Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESALIUS-CV: Evolocumab in High Cardiovascular Risk Patients Without Prior MI or Stroke
NCT03872401Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2019
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial in coronary heart disease (CHD) comparing Placebo with Evolocumab 140 mg Q2W (2 arms). Primary endpoints: Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke at 55.2 months and Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization at 55.2 months. Started Jun 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT03872401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872401.